53
Participants
Start Date
August 24, 2015
Primary Completion Date
August 27, 2020
Study Completion Date
August 27, 2020
Whole Brain Radiation
Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.
Temozolomide
Temozolomide will be administered per label.
ABT-414
ABT-414 will be administered by intravenous infusion
Nagoya University Hospital /ID# 138559, Nagoya
Hiroshima University Hospital /ID# 139399, Hiroshima
Hokkaido University Hospital /ID# 150589, Sapporo
University of Tsukuba Hospital /ID# 140433, Tsukuba
Iwate Medical University Hospital /ID# 149145, Shiwa-gun
Kitasato University Hospital /ID# 148493, Sagamihara-shi
Kumamoto University Hospital /ID# 138558, Kumamoto
Kyoto Prefect Univ Med /ID# 149093, Kyoto
Kyoto University Hospital /ID# 163206, Kyoto
Tohoku University Hospital /ID# 138464, Sendai
Okayama University Hospital /ID# 148674, Okayama
Osaka University Hospital /ID# 140438, Suita-shi
Saitama Medical University International Medical Center /ID# 140361, Hidaka-shi
Shizuoka Cancer Center /ID# 148673, Sunto-gun
Dokkyo Medical University Hospital /ID# 150990, Shimotsuga-gun
National Cancer Center Hospital /ID# 140435, Chuo-ku
Nihon University Itabashi Hospital /ID# 149385, Itabashi-ku
Kyorin University Hospital /ID# 140360, Mitaka-shi
Tokyo Women's Medical University Hospital /ID# 140436, Shinjuku-ku
Chiba Cancer Center /ID# 164375, Chiba
NHO Kyoto Medical Center /ID# 140437, Kyoto
Osaka International Cancer Institute /ID# 148494, Osaka
Lead Sponsor
AbbVie
INDUSTRY